For more information call (888) LUHS-888.
Patients, 18 years and older, must have histologically proven squamous cell carcinoma of the head and neck (oral cavity, oropharynx or larynx), clinical stage T1, N1-2 or T2-3, N0-2, M0. Patients must have had a total resection with curative intent within seven weeks prior to registration to the study, and the pathology must demonstrate intermediate risk factors. Patients must have a chest X-ray, chest CT or a CT/PET of the chest within eight weeks of registration.
The purpose of this study is to compare the effects, good and/or bad, of radiation therapy alone with radiation therapy and cetuximab on you and your cancer. In this study, you will receive either radiation therapy alone or radiation therapy and cetuximab.